LUNGVANTAGE Trademark

Trademark Overview

On Friday, October 19, 2012, a trademark application was filed for LUNGVANTAGE with the United States Patent and Trademark Office. The USPTO has given the LUNGVANTAGE trademark a serial number of 85759136. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, October 4, 2024. This trademark is owned by Viomics, Inc.. The LUNGVANTAGE trademark is filed in the Pharmaceutical Products category with the following description:

Medical testing kits, namely, blood testing kits comprised of medical diagnostic reagents, assays and collection vials for detecting early and late stage lung cancer and potential responsiveness to therapy
lungvantage

General Information

Serial Number85759136
Word MarkLUNGVANTAGE
Filing DateFriday, October 19, 2012
Status710 - CANCELLED - SECTION 8
Status DateFriday, October 4, 2024
Registration Number4499016
Registration DateTuesday, March 18, 2014
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 26, 2013

Trademark Statements

Goods and ServicesMedical testing kits, namely, blood testing kits comprised of medical diagnostic reagents, assays and collection vials for detecting early and late stage lung cancer and potential responsiveness to therapy
Pseudo MarkLUNG ADVANTAGE

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, October 4, 2024
Primary Code005
First Use Anywhere DateMonday, October 8, 2012
First Use In Commerce DateMonday, October 8, 2012

Trademark Owner History

Party NameViomics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressPhoenix, AZ 85004
Party NameViomics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPhoenix, AZ 85004
Party NameViomics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPhoenix, AZ 85004

Trademark Events

Event DateEvent Description
Tuesday, October 23, 2012NEW APPLICATION ENTERED
Thursday, October 25, 2012NOTICE OF PSEUDO MARK MAILED
Monday, February 18, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 6, 2013NOTICE OF PUBLICATION
Tuesday, March 26, 2013PUBLISHED FOR OPPOSITION
Tuesday, May 21, 2013NOA MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 21, 2013SOU TEAS EXTENSION RECEIVED
Thursday, November 21, 2013SOU EXTENSION 1 FILED
Wednesday, October 24, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 18, 2013ASSIGNED TO EXAMINER
Thursday, November 21, 2013TEAS STATEMENT OF USE RECEIVED
Thursday, November 21, 2013USE AMENDMENT FILED
Monday, January 13, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, January 17, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, January 21, 2014SOU EXTENSION 1 GRANTED
Wednesday, January 22, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Saturday, February 8, 2014ASSIGNED TO LIE
Saturday, February 8, 2014LAW OFFICE REGISTRATION REVIEW COMPLETED
Tuesday, February 11, 2014NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED
Tuesday, March 18, 2014REGISTERED-PRINCIPAL REGISTER
Friday, March 13, 2020TEAS SECTION 8 & 15 RECEIVED
Thursday, May 7, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, May 7, 2020NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Saturday, March 18, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, October 4, 2024CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Thursday, May 7, 2020REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, January 21, 2014STATEMENT OF USE PROCESSING COMPLETE
Tuesday, January 21, 2014ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Related Keywords

lungvantage medical kits testing stage late lung potential therapy responsiveness early